

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	4304844
<b>Application Number:</b>	10809635
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	8938
<b>Title of Invention:</b>	DIPEPTIDYL PEPTIDASE INHIBITORS
<b>First Named Inventor/Applicant Name:</b>	Jun Feng
<b>Customer Number:</b>	32793
<b>Filer:</b>	David J. Weitz/Matt Russell
<b>Filer Authorized By:</b>	David J. Weitz
<b>Attorney Docket Number:</b>	DPP-IV-5004-U
<b>Receipt Date:</b>	17-NOV-2008
<b>Filing Date:</b>	24-MAR-2004
<b>Time Stamp:</b>	20:06:49
<b>Application Type:</b>	Utility under 35 USC 111(a)

### Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$990
RAM confirmation Number	4971
Deposit Account	502256
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. Section 1.16 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

## File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Request for Continued Examination (RCE)	DPP4-5004-U_RCE_11-17-2008.pdf	737846 4bb759d6c7f8b542b8d4f9c33ee0bdf7ca761917b3	no	3
Warnings:					
Information:					
2		DPP4-5004-U_Amendment_to_Notice_of Allowance_11-17-2008.pdf	686053 5ba026c048b3f13a12c3a86c765d614e8042549b	yes	16
	Multipart Description/PDF files in .zip description				
	Document Description		Start		End
	Amendment After Final		1		1
	Claims		2		15
	Applicant Arguments/Remarks Made in an Amendment		16		16
Warnings:					
Information:					
3	Information Disclosure Statement (IDS) Filed (SB/08)	DPP4-5004-U_IDS_11-17-2008.pdf	1434342 6f55d43ce152ae9f32e0d005f6e96570508baa1822	no	6
Warnings:					
Information:					
4	NPL Documents	Abstract-of-EP900568-A2.pdf	90691 55092e6d56d4994113f590ed26cb3f59d22384	no	3
Warnings:					
Information:					
5	NPL Documents	Alagarsamy-Synthesis_and_Pharmacological-Med_Chem_lab-XP008084498.pdf	187413 570f9b61802b395c26dd138d4b6dc207c39902	no	2
Warnings:					
Information:					
6	NPL Documents	Belgodere_Chem_Abstacts_1976_85-9.pdf	47519 cca3d318ac148db7c70d9f5ee586c995378c5d797	no	3
Warnings:					

Information:					
7	NPL Documents	CAPLUS_Abstract_104_68665.pdf	46269 ba678409087d984d882d8393257f2587c0808	no	2
Warnings:					
Information:					
8	NPL Documents	CAPLUS_Abstract_105_191027.pdf	43845 9d9d2d9f113388d2553e10277b272cd68e528862	no	2
Warnings:					
Information:					
9	NPL Documents	DB-Beilsetin-DE-1989-XP00232086.pdf	32981 56f1d6d2df6202d822f7c5c3a8e9e27fde015e75	no	2
Warnings:					
Information:					
10	NPL Documents	Desai_Synthesis_anti-HIV-Indian_J_Experimtl_Bio-XP008084509.pdf	284785 212d709d1312b2f5c9cccd41265d016012f9f7765	no	4
Warnings:					
Information:					
11	Foreign Reference	EP00442473A1.pdf	1729807 5282262a6e126cd091bdebc96477fbc5e77d23d	no	40
Warnings:					
Information:					
12	Foreign Reference	EP00748800A2.pdf	3846115 edf8d0c9b29354a5717c94c94ed2e04ab3bdf	no	51
Warnings:					
Information:					
13	Foreign Reference	EP01229024A1.pdf	765065 075adc157f16c5c1a27d99fbbf66b1d9628d01	no	88
Warnings:					
Information:					
14	Foreign Reference	EP01398032A1.pdf	2451091 d19f8bb6d7c727d9bc9c1f131f8d194c7500f	no	85
Warnings:					
Information:					
15	NPL Documents	Kazuo_et_al_XP008082357.pdf	564562 40564e0e0ed2d4bc75ef5f8b842a723683c73862	no	6
Warnings:					

Information:					
16	NPL Documents	Kotani_JMED-1997_40_684-694_XP000652330.pdf	1223662 e1bdc6d6124e02a08c1b27c0b30728c0f62943	no	12
Warnings:					
Information:					
17	NPL Documents	Mall_et_al-Reactivity_Differences_Cis-Trans--J_of_Organic_Chem-52-4812.pdf	356444 8244c6465432313a790174ac2015f6ac0b07481	no	3
Warnings:					
Information:					
18	NPL Documents	Misra-Synthesis_N-aryl-n-Pharmacol-1979_XP008084507.pdf	483736 0bed64ac05d18dc756759186606c3c1efc7c5181	no	8
Warnings:					
Information:					
19	NPL Documents	Molina_et_al-Synthesis-1992-3-DE-XP002390907.pdf	186799 6bc21299470513024194c5d190807414ace68	no	6
Warnings:					
Information:					
20	NPL Documents	Schilling_et_al-CA_143-347172-2005.pdf	34967 f9fb2ce9f6819ac24d3d0014601cc2d0f2e0df	no	2
Warnings:					
Information:					
21	NPL Documents	Tam_et_al-J-ORG-CHEM-1979-44-XP002390906.pdf	347840 5c55d127497c29f55c2d02bd58083d40b106ee	no	8
Warnings:					
Information:					
22	NPL Documents	Wang-Studies_Quinazolinones-Biorgan_Medic_Chem-XP009077496.pdf	330685 44790ba0f8bc7c0fd8b536071054918bf1f11be	no	4
Warnings:					
Information:					
23	Foreign Reference	WO05095381A1.pdf	8641200 18c76980b0b019429d51b7efac644d5c59ce198	no	170
Warnings:					
Information:					
24	Foreign Reference	WO9515309A.pdf	1471747 d17586c2165cc0bdfac7088b4b32788037acid	no	57
Warnings:					

<b>Information:</b>					
25	Foreign Reference	WO27033265A1.pdf	3223471 6a082b7d6d7fec270a087d7d1649cd9961ba54c7a0d	no	58
<b>Warnings:</b>					
<b>Information:</b>					
26	Foreign Reference	WO2007033266_A2_A3.pdf	3652658 4824196141a5e0f9ccc3b223577db407d61726bc9	no	67
<b>Warnings:</b>					
<b>Information:</b>					
27	Foreign Reference	WO2007033350_A1.pdf	3301942 7c72ea22890d21859fbc020221ed81b0b566eb6	no	59
<b>Warnings:</b>					
<b>Information:</b>					
28	NPL Documents	Alagarsamy-Synthesis_Analgesic-Bio_Pharm-Bull_25-11-1432-1435-2002-XP008084513.pdf	291155 0987c13a1303d6480479920bc72b0c30ba1463aa	no	4
<b>Warnings:</b>					
<b>Information:</b>					
29	Fee Worksheet (PTO-06)	fee-info.pdf	32125 5d4f8ebdad7dd678c336211bd4e4cc3273a28b5f96	no	2
<b>Warnings:</b>					
<b>Information:</b>					
Total Files Size (in bytes):			36526815		
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p><b>New Applications Under 35 U.S.C. 111</b>          If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><b>National Stage of an International Application under 35 U.S.C. 371</b>          If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p> <p><b>New International Application Filed with the USPTO as a Receiving Office</b>          If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>					